U.S. Markets closed
  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     
  • Dow 30

    31,176.01
    -12.37 (-0.04%)
     
  • Nasdaq

    13,530.92
    +73.67 (+0.55%)
     
  • Russell 2000

    2,141.42
    -19.20 (-0.89%)
     
  • Crude Oil

    53.03
    -0.28 (-0.53%)
     
  • Gold

    1,869.90
    +3.40 (+0.18%)
     
  • Silver

    26.00
    +0.24 (+0.93%)
     
  • EUR/USD

    1.2174
    +0.0059 (+0.4870%)
     
  • 10-Yr Bond

    1.1090
    +0.0190 (+1.74%)
     
  • Vix

    21.32
    -0.26 (-1.20%)
     
  • GBP/USD

    1.3728
    +0.0073 (+0.5340%)
     
  • USD/JPY

    103.4910
    -0.0790 (-0.0763%)
     
  • BTC-USD

    30,471.23
    -4,480.45 (-12.82%)
     
  • CMC Crypto 200

    602.21
    -77.70 (-11.43%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Affimed (AFMD) Catches Eye: Stock Jumps 8.8%

Zacks Equity Research
·2 min read

Affimed N.V. AFMD was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.82 to $7.03 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Affimed currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Affimed N.V. Price

Affimed N.V. Price
Affimed N.V. Price

Affimed N.V. price | Affimed N.V. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Arcus Biosciences, Inc. RCUS, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Affimed N.V. (AFMD) : Free Stock Analysis Report
 
Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research